PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation
NKGN: 81% | NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 To Progress Into Phase 2 Development In Alzheimer's Disease
DYN: 25% | Dyne Therapeutics Announced Clinical Data From Its Ongoing Phase 1/2 ACHIEVE Trial Of DYNE-101 In Myotonic Dystrophy Type 1 And Phase 1/2 DELIVER Trial Of DYNE-251 In Duchenne Muscular Dystrophy